Review: angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors have the lowest risk for diabetes
- PMID: 17474682
Review: angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors have the lowest risk for diabetes
Comment on
-
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.Lancet. 2007 Jan 20;369(9557):201-7. doi: 10.1016/S0140-6736(07)60108-1. Lancet. 2007. PMID: 17240286